**ASX & Media Release**

# Patrys Receives R&D Tax Incentive Refund

**Melbourne, Australia; 30 October 2025:** Patrys Limited (ASX: PAB, "Patrys" or the "Company"), a therapeutic antibody development company, is pleased to announce that its wholly-owned subsidiary Nucleus Therapeutics Pty Ltd has received a rebate of $807,000 for the 2024/2025 financial year under the Federal Government's R&D Tax Incentive scheme.

The Research & Development (R&D) Tax Incentive helps companies innovate and grow by providing a tax offset for eligible research and development.

**-Ends-**

This announcement is authorised for release by the Board of Directors of Patrys Limited.


**For further information, please contact:**

**General enquiries**
Peter Christie
Non-Executive Chair
P: + 61 3 9670 3273
info@patrys.com

**Registered Office Address**
Suite 2, Level 11, 385 Bourke Street,
Melbourne, VIC, 3000


**About Patrys Limited**
Based in Melbourne, Australia, Patrys (ASX:PAB) is focused on the development of its deoxymab platform of cell-penetrating antibodies as therapies for a range of different indications. More information can be found at www.patrys.com.